Company Overview of Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics, Inc. develops new therapies and re-positions existing therapies to meet serious unmet needs. Its development portfolio includes Metformin DR, a delayed-release formulation of metformin that releases metformin primarily in the distal small intestine and restricts metformin to the bowel primarily suited for patients who cannot use metformin owing to contraindications or poor tolerability. The company’s Metformin DR solution serves as an initial agent for the treatment of type 2 diabetes. The company was incorporated in 2009 and is headquartered in San Diego, California.
11975 El Camino Real
San Diego, CA 92130
Founded in 2009
Key Executives for Elcelyx Therapeutics, Inc.
Chief Executive Officer, President, Member of Management Board and Director
Senior Vice President of Finance & Operations
Senior Vice President of R&D
Vice President of Business Development
Vice President of Regulatory Affairs & Quality Assurance
Compensation as of Fiscal Year 2017.
Elcelyx Therapeutics, Inc. Key Developments
Elcelyx Therapeutics Elects Sandy Mahatme to Board of Directors as Independent Director
Oct 12 16
Elcelyx Therapeutics announced that Sandesh "Sandy" Mahatme has been appointed to its Board of Directors as an independent director. Mahatme is currently senior vice president, chief financial officer at Sarepta Therapeutics. Prior to joining Sarepta in 2012, Mahatme worked at Celgene Corporation, where he served in various roles, including senior vice president of corporate development, senior vice president of finance, corporate treasurer and head of tax.
Elcelyx Therapeutics Completes Enrollment in Phase 2b Clinical Trial of Metformin Delayed Release for Type 2 Diabetes
May 25 16
Elcelyx Therapeutics announced that it has completed enrollment of its Phase 2b clinical trial to evaluate Metformin Delayed Release (DR) in subjects with type 2 diabetes. The primary endpoint of this dose-ranging study is change in HbA1c from baseline at 16 weeks compared with placebo. The trial results are expected in the fourth quarter of 2016 and will serve to further document metformin's gut mediated site of action and confirm doses to be studied in Phase 3 in patients with advanced renal disease. These data will complement results from Elcelyx's previous Phase 2 clinical trial that showed reductions in fasting plasma glucose over 12 weeks with Metformin DR compared with placebo. Although metformin is the preferred agent for the treatment of type 2 diabetes, patients often discontinue it due to renal impairment and gastrointestinal intolerance. Physicians face numerous challenges with metformin use in patients with renal disease including the need to monitor renal function status to ensure appropriate use. Insulin, which has unique challenges from a patient management and safety perspective, is often the only treatment option available for these patients. The multicenter, randomized, Phase 2b dose-ranging study enrolled 571 subjects and is evaluating the glycemic effects of several doses Metformin DR (600, 900, 1,200 and 1,500 milligrams, once daily) compared with placebo in subjects with type 2 diabetes. The study also includes a single-blind comparator arm of subjects receiving 2,000 milligrams of Metformin Immediate Release (IR) per day, administered as equally divided doses (1,000 milligrams of Metformin IR twice daily). In addition to measuring HbA1c over 16 weeks, safety and tolerability will be evaluated.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries